IBDEI2W6 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,46127,1,3,0)
 ;;=3^Myopia,Bilateral
 ;;^UTILITY(U,$J,358.3,46127,1,4,0)
 ;;=4^H52.13
 ;;^UTILITY(U,$J,358.3,46127,2)
 ;;=^5006266
 ;;^UTILITY(U,$J,358.3,46128,0)
 ;;=H52.03^^176^2300^33
 ;;^UTILITY(U,$J,358.3,46128,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46128,1,3,0)
 ;;=3^Hypermetropia,Bilateral
 ;;^UTILITY(U,$J,358.3,46128,1,4,0)
 ;;=4^H52.03
 ;;^UTILITY(U,$J,358.3,46128,2)
 ;;=^5006262
 ;;^UTILITY(U,$J,358.3,46129,0)
 ;;=H52.4^^176^2300^45
 ;;^UTILITY(U,$J,358.3,46129,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46129,1,3,0)
 ;;=3^Presbyopia
 ;;^UTILITY(U,$J,358.3,46129,1,4,0)
 ;;=4^H52.4
 ;;^UTILITY(U,$J,358.3,46129,2)
 ;;=^98095
 ;;^UTILITY(U,$J,358.3,46130,0)
 ;;=H25.11^^176^2300^10
 ;;^UTILITY(U,$J,358.3,46130,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46130,1,3,0)
 ;;=3^Cataract,Nuclear Age-Rel,Right Eye
 ;;^UTILITY(U,$J,358.3,46130,1,4,0)
 ;;=4^H25.11
 ;;^UTILITY(U,$J,358.3,46130,2)
 ;;=^5005284
 ;;^UTILITY(U,$J,358.3,46131,0)
 ;;=H25.12^^176^2300^9
 ;;^UTILITY(U,$J,358.3,46131,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46131,1,3,0)
 ;;=3^Cataract,Nuclear Age-Rel,Left Eye
 ;;^UTILITY(U,$J,358.3,46131,1,4,0)
 ;;=4^H25.12
 ;;^UTILITY(U,$J,358.3,46131,2)
 ;;=^5005285
 ;;^UTILITY(U,$J,358.3,46132,0)
 ;;=Z98.49^^176^2300^8
 ;;^UTILITY(U,$J,358.3,46132,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46132,1,3,0)
 ;;=3^Cataract Extraction Status,Unspec Eye
 ;;^UTILITY(U,$J,358.3,46132,1,4,0)
 ;;=4^Z98.49
 ;;^UTILITY(U,$J,358.3,46132,2)
 ;;=^5063739
 ;;^UTILITY(U,$J,358.3,46133,0)
 ;;=H04.123^^176^2300^23
 ;;^UTILITY(U,$J,358.3,46133,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46133,1,3,0)
 ;;=3^Dry Eye Syndrome,Bilateral Lacrimal Glands
 ;;^UTILITY(U,$J,358.3,46133,1,4,0)
 ;;=4^H04.123
 ;;^UTILITY(U,$J,358.3,46133,2)
 ;;=^5004465
 ;;^UTILITY(U,$J,358.3,46134,0)
 ;;=H01.009^^176^2300^6
 ;;^UTILITY(U,$J,358.3,46134,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46134,1,3,0)
 ;;=3^Blepharitis,Unspec
 ;;^UTILITY(U,$J,358.3,46134,1,4,0)
 ;;=4^H01.009
 ;;^UTILITY(U,$J,358.3,46134,2)
 ;;=^5133381
 ;;^UTILITY(U,$J,358.3,46135,0)
 ;;=H40.023^^176^2300^31
 ;;^UTILITY(U,$J,358.3,46135,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46135,1,3,0)
 ;;=3^Glaucoma Suspect,High Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,46135,1,4,0)
 ;;=4^H40.023
 ;;^UTILITY(U,$J,358.3,46135,2)
 ;;=^5005730
 ;;^UTILITY(U,$J,358.3,46136,0)
 ;;=H40.053^^176^2300^42
 ;;^UTILITY(U,$J,358.3,46136,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46136,1,3,0)
 ;;=3^Ocular Hypertension,Bilateral
 ;;^UTILITY(U,$J,358.3,46136,1,4,0)
 ;;=4^H40.053
 ;;^UTILITY(U,$J,358.3,46136,2)
 ;;=^5005742
 ;;^UTILITY(U,$J,358.3,46137,0)
 ;;=E11.9^^176^2300^20
 ;;^UTILITY(U,$J,358.3,46137,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46137,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,46137,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,46137,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,46138,0)
 ;;=E11.39^^176^2300^19
 ;;^UTILITY(U,$J,358.3,46138,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46138,1,3,0)
 ;;=3^DM Type 2 w/ Ophthalmic Complications
 ;;^UTILITY(U,$J,358.3,46138,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,46138,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,46139,0)
 ;;=H59.039^^176^2300^7
 ;;^UTILITY(U,$J,358.3,46139,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46139,1,3,0)
 ;;=3^CME Mac Edema,Unspec Eye
 ;;^UTILITY(U,$J,358.3,46139,1,4,0)
 ;;=4^H59.039
